4.7 Article

Mechanism of DNA resection during intrachromosomal recombination and immunoglobulin class switching

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 210, Issue 1, Pages 115-123

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20121975

Keywords

-

Funding

  1. National Institutes of Health (NIH) [AI037526, CA93484]
  2. NIH Intramural Research Program of National Insitute of Arthritis and Musculoskeletal and Skin Diseases
  3. National Institute on Aging

Ask authors/readers for more resources

DNA double-strand breaks (DSBs) are byproducts of normal cellular metabolism and obligate intermediates in antigen receptor diversification reactions. These lesions are potentially dangerous because they can lead to deletion of genetic material or chromosome translocation. The chromatin-binding protein 53BP1 and the histone variant H2AX are required for efficient class switch (CSR) and V(D)J recombination in part because they protect DNA ends from resection and thereby favor nonhomologous end joining (NHEJ). Here, we examine the mechanism of DNA end resection in primary B cells. We find that resection depends on both CtBP-interacting protein (CtIP, Rbbp8) and exonuclease 1 (Exo1). Inhibition of CtIP partially rescues the CSR defect in 53BP1- and H2AX-deficient lymphocytes, as does interference with the RecQ helicases Bloom (Blm) and Werner (Wrn). We conclude that CtIP, Exo1, and RecQ helicases contribute to the metabolism of DNA ends during DSB repair in B lymphocytes and that minimizing resection favors efficient CSR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques

Koen K. A. Van Rompay, Lark L. Coffey, Tania Kapoor, Anna Gazumyan, Rebekah I. Keesler, Andrea Jurado, Avery Peace, Marianna Agudelo, Jennifer Watanabe, Jodie Usachenko, Anil Singapuri, Ramya Immareddy, Amir Ardeshir, Jackson B. Stuart, Stylianos Bournazos, Jeffrey V. Ravetch, Paul J. Balderes, Ivo C. Lorenz, Shannon R. Esswein, Jennifer R. Keeffe, Pamela J. Bjorkman, Qiao Wang, Charles M. Rice, Margaret R. MacDonald, Michel C. Nussenzweig, Davide F. Robbiani

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Multidisciplinary Sciences

Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody

Shannon R. Esswein, Harry B. Gristick, Andrea Jurado, Avery Peace, Jennifer R. Keeffe, Yu E. Lee, Alisa V. Voll, Mohsan Saeed, Michel C. Nussenzweig, Charles M. Rice, Davide F. Robbiani, Margaret R. MacDonald, Pamela J. Bjorkman

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Immunology

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Alexandra Schafer, Frauke Muecksch, Julio C. C. Lorenzi, Sarah R. Leist, Melissa Cipolla, Stylianos Bournazos, Fabian Schmidt, Rachel M. Maison, Anna Gazumyan, David R. Martinez, Ralph S. Baric, Davide F. Robbiani, Theodora Hatziioannou, Jeffrey Ravetch, Paul D. Bieniasz, Richard A. Bowen, Michel C. Nussenzweig, Timothy P. Sheahan

Summary: The study shows that combined use of hu-mAbs is effective for prevention and therapy of SARS-CoV-2 infection, but in vivo protection is influenced by intact effector function.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Article Multidisciplinary Sciences

Evolution of antibody immunity to SARS-CoV-2

Christian Gaebler, Zijun Wang, Julio C. C. Lorenzi, Frauke Muecksch, Shlomo Finkin, Minami Tokuyama, Alice Cho, Mila Jankovic, Dennis Schaefer-Babajew, Thiago Y. Oliveira, Melissa Cipolla, Charlotte Viant, Christopher O. Barnes, Yaron Bram, Gaelle Breton, Thomas Hagglof, Pilar Mendoza, Arlene Hurley, Martina Turroja, Kristie Gordon, Katrina G. Millard, Victor Ramos, Fabian Schmidt, Yiska Weisblum, Divya Jha, Michael Tankelevich, Gustavo Martinez-Delgado, Jim Yee, Roshni Patel, Juan Dizon, Cecille Unson-O'Brien, Irina Shimeliovich, Davide F. Robbiani, Zhen Zhao, Anna Gazumyan, Robert E. Schwartz, Theodora Hatziioannou, Pamela J. Bjorkman, Saurabh Mehandru, Paul D. Bieniasz, Marina Caskey, Michel C. Nussenzweig

Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.

NATURE (2021)

Article Cell Biology

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Zijun Wang, Julio C. C. Lorenzi, Frauke Muecksch, Shlomo Finkin, Charlotte Viant, Christian Gaebler, Melissa Cipolla, Hans-Heinrich Hoffman, Thiago Y. Oliveira, Deena A. Oren, Victor Ramos, Lilian Nogueira, Eleftherios Michailidis, Davide F. Robbiani, Anna Gazumyan, Charles M. Rice, Theodora Hatziioannou, Paul D. Bieniasz, Marina Caskey, Michel C. Nussenzweig

Summary: The IgA response to SARS-CoV-2 was characterized in a cohort of 149 convalescent individuals after COVID-19 diagnosis. IgA responses in plasma generally correlated with IgG responses, and B cells producing IgM, IgG, and IgA were derived from common progenitor cells. Notably, IgA dimers were found to be 15 times more potent than IgA monomers against SARS-CoV-2, suggesting their potential value for protection and vaccine efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Article Hematology

miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms

Tomasz Sewastianik, Juerg R. Straubhaar, Jian-Jun Zhao, Mehmet K. Samur, Keith Adler, Helen E. Tanton, Vignesh Shanmugam, Omar Nadeem, Peter S. Dennis, Vinodh Pillai, Jianli Wang, Meng Jiang, Jianhong Lin, Ying Huang, Daniel Brooks, Mary Bouxsein, David M. Dorfman, Geraldine S. Pinkus, Davide F. Robbiani, Irene M. Ghobrial, Bogdan Budnik, Petr Jarolim, Nikhil C. Munshi, Kenneth C. Anderson, Ruben D. Carrasco

Summary: The deletion of miR-15a/16-1 cluster in murine GC B cells induces moderate but widespread molecular and functional changes, leading to the development of mature B-cell neoplasms resembling human extramedullary plasmacytoma and lymphoma. The low expression levels of miR-15a/16 in human primary EP, primarily associated with del(13q) loss, highlights the tumor-suppressor role of this cluster in plasma cell and B-cell malignancies.

BLOOD (2021)

Article Immunology

Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease

Marianna Agudelo, Martin Palus, Jennifer R. Keeffe, Filippo Bianchini, Pavel Svoboda, Jiri Salat, Avery Peace, Anna Gazumyan, Melissa Cipolla, Tania Kapoor, Francesca Guidetti, Kai-Hui Yao, Jana Elsterova, Dana Teislerova, Ales Chrdle, Vaclav Honig, Thiago Oliveira, Anthony P. West, Yu E. Lee, Charles M. Rice, Margaret R. MacDonald, Pamela J. Bjorkman, Daniel Ruzek, Davide F. Robbiani, Michel C. Nussenzweig

Summary: The study revealed the human neutralizing antibody response to TBEV, showing that the most potent neutralizing antibodies were found in individuals who recovered from natural infection. These antibodies also neutralized other tick-borne flaviviruses, and structural analysis identified a conserved epitope near the lateral ridge of EDIII. Prophylactic or early therapeutic antibody administration was effective at low doses in mice lethally infected with TBEV.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Article Multidisciplinary Sciences

Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice

Raoul De Gasparo, Mattia Pedotti, Luca Simonelli, Petr Nickl, Frauke Muecksch, Irene Cassaniti, Elena Percivalle, Julio C. C. Lorenzi, Federica Mazzola, Davide Magri, Tereza Michalcikova, Jan Haviernik, Vaclav Honig, Blanka Mrazkova, Natalie Polakova, Andrea Fortova, Jolana Tureckova, Veronika Iatsiuk, Salvatore Di Girolamo, Martin Palus, Dagmar Zudova, Petr Bednar, Ivana Bukova, Filippo Bianchini, Dora Mehn, Radim Nencka, Petra Strakova, Oto Pavlis, Jan Rozman, Sabrina Gioria, Jose Camilla Sammartino, Federica Giardina, Stefano Gaiarsa, Qiang Pan-Hammarstrom, Christopher O. Barnes, Pamela J. Bjorkman, Luigi Calzolai, Antonio Piralla, Fausto Baldanti, Michel C. Nussenzweig, Paul D. Bieniasz, Theodora Hatziioannou, Jan Prochazka, Radislav Sedlacek, Davide F. Robbiani, Daniel Ruzek, Luca Varani

Summary: The bispecific IgG1-like molecule CoV-X2 can simultaneously bind two independent sites on the RBD, prevent spike binding to ACE2, neutralize SARS-CoV-2 and its variants, and protect mice from disease in a mouse model of SARS-CoV-2 infection. This demonstrates the feasibility and efficacy of targeting non-overlapping RBD epitopes with IgG-like bispecific antibodies.

NATURE (2021)

Editorial Material Immunology

A dark side to NS1 antibodies?

Davide F. Robbiani, Daniel Ruzek

Summary: The NS1 protein of flaviviruses has become a focus of research for its potential in vaccine and immunotherapeutic development. However, a recent study has revealed a potential dark side to NS1, linking it to the development of self-reactive antibodies.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Article Multidisciplinary Sciences

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Allison J. Greaney, Tyler N. Starr, Christopher O. Barnes, Yiska Weisblum, Fabian Schmidt, Marina Caskey, Christian Gaebler, Alice Cho, Marianna Agudelo, Shlomo Finkin, Zijun Wang, Daniel Poston, Frauke Muecksch, Theodora Hatziioannou, Paul D. Bieniasz, Davide F. Robbiani, Michel C. Nussenzweig, Pamela J. Bjorkman, Jesse D. Bloom

Summary: The study found that although the human immune system can produce antibodies that target diverse RBD epitopes, in practice, the polyclonal response to infection tends to be skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.

NATURE COMMUNICATIONS (2021)

Article Biochemistry & Molecular Biology

An NK-like CAR T cell transition in CAR T cell dysfunction

Charly R. Good, M. Angela Aznar, Shunichiro Kuramitsu, Parisa Samareh, Sangya Agarwal, Greg Donahue, Kenichi Ishiyama, Nils Wellhausen, Austin K. Rennels, Yujie Ma, Lifeng Tian, Sonia Guedan, Katherine A. Alexander, Zhen Zhang, Philipp C. Rommel, Nathan Singh, Karl M. Glastad, Max W. Richardson, Keisuke Watanabe, Janos L. Tanyi, Mark H. O'Hara, Marco Ruella, Simon F. Lacey, Edmund K. Moon, Stephen J. Schuster, Steven M. Albelda, Lewis L. Lanier, Regina M. Young, Shelley L. Berger, Carl H. June

Summary: CAR T cell therapy has achieved success in hematological malignancies but faces challenges in solid tumors due to CAR T cell exhaustion. Dysfunction of CAR T cells in solid tumors is associated with CD8+ T-to-NK-like T cell transition, and genetic downregulation of ID3 and SOX4 expression can improve the efficacy of CAR T cell therapy.
Review Immunology

Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy

Nils Wellhausen, Sangya Agarwal, Philipp C. Rommel, Saar Gill, Carl H. June

Summary: T cells engineered with transgenes such as CAR or modified TCR have become a new pillar of cancer therapy. The use of CRISPR/Cas gene-editing tools provides even stronger and more precise control over the fate and function of engineered T cell therapies. This review summarizes the CRISPR/Cas techniques used in preclinical research and outlines those being tested in clinical trials.

CURRENT OPINION IN IMMUNOLOGY (2022)

Article Multidisciplinary Sciences

Potentiating adoptive cell therapy using synthetic IL-9 receptors

Anusha Kalbasi, Mikko Siurala, Leon L. Su, Mito Tariveranmoshabad, Lora K. Picton, Pranali Ravikumar, Peng Li, Jian-Xin Lin, Helena Escuin-Ordinas, Tong Da, Sarah V. Kremer, Amy L. Sun, Sofia Castelli, Sangya Agarwal, John Scholler, Decheng Song, Philipp C. Rommel, Enrico Radaelli, Regina M. Young, Warren J. Leonard, Antoni Ribas, Carl H. June, K. Christopher Garcia

Summary: Synthetic receptor signaling has the potential to enhance the functions of adoptively transferred T cells, improving their ability to treat solid tumors. By designing chimeric receptors with an orthogonal IL-2 receptor extracellular domain fused with the intracellular domain of receptors for common gamma-chain cytokines IL-4, IL-7, IL-9, and IL-21, T cells can be activated to elicit corresponding gamma(e) cytokine signals. This activation leads to improved anti-tumor efficacy in challenging mouse models of melanoma and pancreatic cancer.

NATURE (2022)

Article Immunology

Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein

Filippo Bianchini, Virginia Crivelli, Morgan E. Abernathy, Concetta Guerra, Martin Palus, Jonathan Muri, Harold Marcotte, Antonio Piralla, Mattia Pedotti, Raoul De Gasparo, Luca Simonelli, Milos Matkovic, Chiara Toscano, Maira Biggiogero, Veronica Calvaruso, Pavel Svoboda, Tomas Cervantes Rincon, Tommaso Fava, Lucie Podesvova, Akanksha A. Shanbhag, Andrea Celoria, Jacopo Sgrignani, Michal Stefanik, Vaclav Honig, Veronika Pranclova, Tereza Michalcikova, Jan Prochazka, Giuditta Guerrini, Dora Mehn, Annalisa Clabbattini, Hassan Abolhassani, David Jarrossay, Mariagrazia Uguccioni, Donata Medaglini, Qiang Pan-Hammarstroem, Luigi Calzolai, Daniel Fernandez, Fausto Baldanti, Alessandra Franzetti-Pellanda, Christian Garzoni, Radislav Sedlacek, Daniel Ruzek, Luca Varani, Andrea Cavalli, Christopher O. Barnes, Davide F. Robbiani

Summary: Using coldspot-guided antibody discovery, neutralizing antibodies to highly conserved viral epitopes were identified. Antibody fp.006 binds the fusion peptide and cross-reacts against coronaviruses. Antibody hr2.016 targets the stem helix and neutralizes SARS-CoV-2 variants. Antibody sd1.040 binds to subdomain 1 and synergizes with antibody rbd.042 for neutralization.

SCIENCE IMMUNOLOGY (2023)

Article Immunology

Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course

Jonathan Muri, Valentina Cecchinato, Andrea Cavalli, Akanksha A. A. Shanbhag, Milos Matkovic, Maira Biggiogero, Pier Andrea Maida, Jacques Moritz, Chiara Toscano, Elaheh Ghovehoud, Raffaello Furlan, Franca Barbic, Antonio Voza, Guendalina De Nadai, Carlo Cervia, Yves Zurbuchen, Patrick Taeschler, Lilly A. Murray, Gabriela Danelon-Sargenti, Simone Moro, Tao Gong, Pietro Piffaretti, Filippo Bianchini, Virginia Crivelli, Lucie Podesvova, Mattia Pedotti, David Jarrossay, Jacopo Sgrignani, Sylvia Thelen, Mario Uhr, Enos Bernasconi, Andri Rauch, Antonio Manzo, Adrian Ciurea, Marco B. L. Rocchi, Luca Varani, Bernhard Moser, Barbara Bottazzi, Marcus Thelen, Brian A. Fallon, Onur Boyman, Alberto Mantovani, Christian Garzoni, Alessandra Franzetti-Pellanda, Mariagrazia Uguccioni, Davide F. Robbiani

Summary: We found that antibodies against specific chemokines are commonly present in COVID-19 convalescents and are associated with favorable disease outcomes and a decreased risk of long COVID development at 1 year post-infection. These chemokine antibodies are also found in HIV-1 infection and autoimmune disorders, but target different chemokines compared to COVID-19. Monoclonal antibodies derived from COVID-19 convalescents that bind to the chemokine N-loop impair cell migration. Naturally occurring chemokine antibodies may modulate the inflammatory response and have therapeutic potential.

NATURE IMMUNOLOGY (2023)

No Data Available